GUD vs. BHC, THCX, CRON, TLRY, ACB, WEED, FIRE, CPH, OGI, and EPI
Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Bausch Health Companies (BHC), Hydropothecary (THCX), Cronos Group (CRON), Tilray Brands (TLRY), Aurora Cannabis (ACB), Canopy Growth (WEED), Supreme Cannabis (FIRE), Cipher Pharmaceuticals (CPH), Organigram (OGI), and ESSA Pharma (EPI). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Knight Therapeutics vs. Its Competitors
Bausch Health Companies (TSE:BHC) and Knight Therapeutics (TSE:GUD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.
In the previous week, Bausch Health Companies had 3 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for Bausch Health Companies and 0 mentions for Knight Therapeutics. Bausch Health Companies' average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.
Knight Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Knight Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.
Bausch Health Companies has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.
79.0% of Bausch Health Companies shares are held by institutional investors. Comparatively, 12.6% of Knight Therapeutics shares are held by institutional investors. 11.3% of Bausch Health Companies shares are held by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Bausch Health Companies has a net margin of -1.88% compared to Knight Therapeutics' net margin of -8.81%. Bausch Health Companies' return on equity of 15.87% beat Knight Therapeutics' return on equity.
Knight Therapeutics has a consensus price target of C$7.15, indicating a potential upside of 16.64%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Knight Therapeutics is more favorable than Bausch Health Companies.
Summary
Bausch Health Companies and Knight Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Knight Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Knight Therapeutics Competitors List
Related Companies and Tools
This page (TSE:GUD) was last updated on 7/12/2025 by MarketBeat.com Staff
Free GUD Stock Alerts